

Mark E. Augustine

Mark Augustine has fifteen years of healthcare investment experience and is founder of Augustine Consulting, which provides proprietary biotechnology industry research to various hedge fund and mutual fund clients. Previously, Mr. Augustine was a sell-side biotechnology stock analyst for nine years, most recently at Credit Suisse, where he led the biotechnology research team for nearly four years and was an Institutional Investor runner-up in 2004. Mr. Augustine has also worked in venture capital at Canaan Partners. He is a graduate of Yale College and the Harvard Business School.